The J&J vaccine had been given to about 370,000 health workers in SA by Friday, said professor Glenda Gray, co-principal investigator of the Sisonke J&J implementation study which provides the shots.
But vaccine hesitancy among health workers has gone up following a brief pause in the study in April to investigate extremely rare and unusual blood clots linked to the vaccinations — about one in a million.
“We have seen an increase in vaccine hesitancy. Before the pause we were inundated but it has affected our uptake. It impacted on confidence and there is a lot more hesitancy,” said Gray.
“Even though the vaccine is reactogenic and can cause side-effects, people will likely be much worse off if they get Covid,” said Gray, president of the SA Medical Research Council.
Gray said they were vaccinating about 10,000 to 15,000 people a day and were on track to finish the Sisonke vaccination of half a million health workers by the end of next week, after which the national programme will kick in to vaccinate the remaining 700,000.
In the real-world, observational study in Israel, where about 70% of the population older than 16 has been vaccinated, two doses of the Pfizer-BioNTech vaccine provided more than 95% protection against severe disease and death.
Before people got their second shot (this has been developed as a double-dose vaccine) the efficacy was lower at 58% protection against infection, 76% protection against hospitalisation and 77% against death.
Covid-19
Pfizer Covid-19 vaccine for SA has '95% success rate'
The Pfizer Covid-19 vaccine, 325,000 doses of which landed in Johannesburg this week, offers 95% protection against hospitalisation and death, according to a big new study from Israel published in the Lancet medical journal this week.
The latest results are further evidence that the two Covid-19 vaccines to be rolled out to South Africans from May 17 — the Pfizer/BioNTech and Johnson & Johnson vaccines — offer real protection.
The J&J vaccine is the only Covid-19 vaccine tested in a big study, of 44,000 participants, against the B1.351 variant of Covid-19 dominant in SA. The vaccine was found to offer 64% protection against severe disease and death. It also has the advantage of being a single-dose vaccine.
Scientists, clinicians and health officials warned this week that Covid-19 cases were picking up in SA “after a lull”, and vaccinating at speed and scale was critical to control the third wave.
The J&J vaccine had been given to about 370,000 health workers in SA by Friday, said professor Glenda Gray, co-principal investigator of the Sisonke J&J implementation study which provides the shots.
But vaccine hesitancy among health workers has gone up following a brief pause in the study in April to investigate extremely rare and unusual blood clots linked to the vaccinations — about one in a million.
“We have seen an increase in vaccine hesitancy. Before the pause we were inundated but it has affected our uptake. It impacted on confidence and there is a lot more hesitancy,” said Gray.
“Even though the vaccine is reactogenic and can cause side-effects, people will likely be much worse off if they get Covid,” said Gray, president of the SA Medical Research Council.
Gray said they were vaccinating about 10,000 to 15,000 people a day and were on track to finish the Sisonke vaccination of half a million health workers by the end of next week, after which the national programme will kick in to vaccinate the remaining 700,000.
In the real-world, observational study in Israel, where about 70% of the population older than 16 has been vaccinated, two doses of the Pfizer-BioNTech vaccine provided more than 95% protection against severe disease and death.
Before people got their second shot (this has been developed as a double-dose vaccine) the efficacy was lower at 58% protection against infection, 76% protection against hospitalisation and 77% against death.
A study involving 800 participants in SA who got the Pfizer vaccine showed that nobody who got the Pfizer vaccine got Covid-19, while nine people on the placebo did — six infected by the dominant variant.
In a real-world study in Qatar of more than 200,000 people, reported in the New England Medical Journal this week, scientists found the Pfizer vaccine was more than 95% effective at preventing severe, critical or fatal disease from any form of the coronavirus, including Covid-19 caused by the B.1.351 variant.
The effectiveness at preventing infection dropped to 72% from 75% against the variant common in SA.
The Covid-19 vaccines in use globally — 1.23-billion people had been vaccinated worldwide by Friday, according to Bloomberg — run the risk of very rare and unusual blood clots.
You have a greater chance of being struck by lightning — twice — than getting a blood clot from a Covid-19 vaccine, said Wits professor Barry Jacobson, president of the SA Society of Thrombosis and Hemostatis, at the time of the J&J pause mid-April.
The risk of developing these clots after getting vaccinated — with doses of the J&J, Oxford-AstraZeneca or the mRNA vaccines of Pfizer and Moderna — is much lower than the risk of clotting after being infected with Covid-19, a study by Oxford University in April found.
The clotting disorder, which affects the brain — known as cerebral venous thrombosis, or CVT — is about 100 times greater among people who get Covid-19 than normal, the Oxford team reported.
Among the health workers, a few individuals have had allergic reactions and been successfully treated, said Gray. Symptoms of headaches and fatigue after getting a shot are common but mild.
Pfizer SA country manager Rhulani Nhlaniki said the vaccines’ arrival this week was a “momentous” occasion for the company and “a huge boost to the SA government’s efforts to roll out the Covid-19 vaccines to the SA people as quickly as possible”.
READ MORE